$JSPR

Jasper Therapeutics, Inc.

CIK:0001788028|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses
Research and development	$ 5,135	$ 21,196	$ 10,949	$ 37,353
General and administrative	4,072	5,880	9,210	11,525
Total operating expenses	9,207	27,076	20,159	48,878
Loss from operations	(9,207)	(27,076)	(20,159)	(48,878)
Interest income	82	437	246	1,061
Change in fair value of warrant liability	3,980		13,620
Other income (expense), net	2,385	(84)	2,359	(147)
Total other income, net	6,447	353	16,225	914
Net loss and comprehensive loss	$ (2,760)	$ (26,723)	$ (3,934)	$ (47,964)
Net loss per share attributable to common stockholders, basic (in Dollars per share)	$ (0.1)	$ (1.74)	$ (0.14)	$ (3.16)
Net loss per share attributable to common stockholders, diluted (in Dollars per share)	$ (0.1)	$ (1.74)	$ (0.14)	$ (3.16)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares)	28,696,937	15,333,962	28,684,447	15,178,904
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in Shares)	28,696,937	15,333,962	28,684,447	15,178,904

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows used in operating activities
Net loss	$ (3,934)	$ (47,964)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	42	537
Non-cash lease expense	374	508
Stock-based compensation expense	1,187	3,628
Change in fair value of warrant liability	(13,620)
(Gain) loss on disposal of property and equipment	(80)	2
Gain on reversal of CIRM grant liability	(2,264)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	2,113	718
Other non-current assets	70	628
Accounts payable	(3,442)	4,007
Accrued expenses and other current liabilities	(948)	391
Operating lease liability	(965)	(750)
Net cash used in operating activities	(21,467)	(38,295)
Cash flows provided by investing activities
Purchases of property and equipment		(7)
Proceeds from sales of property and equipment	80	12
Net cash provided by investing activities	80	5
Cash flows from financing activities
Proceeds from issuance of common stock through ATM and underwritten offerings, net		5,940
Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plan	9	223
Net cash provided by financing activities	9	6,163
Net decrease in cash, cash equivalents and restricted cash	(21,378)	(32,127)
Cash, cash equivalents and restricted cash at beginning of the period	29,109	72,054
Cash, cash equivalents and restricted cash at end of the period	7,731	39,927
Supplemental and non-cash items reconciliations
Right-of-use asset obtained in exchange for lease liabilities		$ 1,092

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 7,314	$ 28,692
Restricted cash, current	417
Prepaid expenses and other current assets	3,840	5,953
Total current assets	11,571	34,645
Property and equipment, net	60	102
Operating lease right-of-use assets	128	502
Restricted cash, non-current		417
Other non-current assets	43	113
Total assets	11,802	35,779
Current liabilities:
Accounts payable	2,778	6,220
Operating lease liabilities	270	1,235
Accrued expenses and other current liabilities	4,797	5,745
Total current liabilities	7,845	13,200
Warrant liability	2,544	16,164
Other non-current liabilities		2,264
Total liabilities	10,389	31,628
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock: $0.0001 par value — 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; none issued and outstanding at June 30, 2026 and December 31, 2025
Common stock: $0.0001 par value — 492,000,000 shares authorized at June 30, 2026 and December 31, 2025; 28,079,552 and 27,996,819 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	3	3
Additional paid-in capital	322,014	320,818
Accumulated deficit	(320,604)	(316,670)
Total stockholders’ equity	1,413	4,151
Total liabilities and stockholders’ equity	$ 11,802	$ 35,779